LUND, Sweden, May 31, 2023 /PRNewswire/ -- The number
of shares and votes in Immunovia AB (publ) ("Immunovia") have
changed as a result of new shares being issued in the rights issue
resolved by the board of directors on 20
February 2023, subject to approval from the extraordinary
general meeting on 16 March
2023.
Through the rights issue, the number of outstanding shares and
votes have increased by 22,655,917, from 22,631,581 to 45,287,498.
The share capital has increased by SEK 1,132,795.85, from
SEK 1,131,579.05 to SEK 2,264,374.90.
For more information, please contact:
Karin Almqvist Liwendahl
CFO
kain.almqvist.liwendahl@immunovia.com
+46 70 911 56 08
The information was submitted for publication, through the
agency of the contact person set out above, at 11:45 CET on
31 May 2023.
About Immunovia
Immunovia is a diagnostic company with the vision to revolutionize
blood-based diagnostics and increase survival rates for patients
with cancer.
Our first product, IMMray™ PanCan-d is the only blood test
currently available specifically for the early detection of
pancreatic cancer. The test has unmatched clinical performance.
Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers,
leading experts and patient advocacy groups globally to make this
test available to all high-risk pancreatic cancer
groups.
The USA, the first market in
which IMMray™ PanCan-d is commercially available, is the world's
largest market for the detection of pancreatic cancer with an
estimated, addressable market size of 1.8 million individuals per
year who could benefit from our test.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com
The following files are available for download:
https://mb.cision.com/Main/13121/3777774/2096139.pdf
|
Press release
(PDF)
|
View original
content:https://www.prnewswire.co.uk/news-releases/change-in-number-of-shares-and-votes-in-immunovia-ab-publ-301838450.html